Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 18/20 | 0.76 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.76 |
| ▸ | ESRRG | P62508 | 5/20 | 0.76 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | HTR6 | P50406 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.55 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.55 |
| ▸ | ESRRB | O95718 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL906340 | 1.00 | ESR1 (0.76) | ESR1CYP19A1ESRRGESR2LMNA | |
| SCHEMBL9099398 | 1.00 | ESR1 (0.76) | ESR1CYP19A1ESRRGESR2LMNA | |
| SCHEMBL906306 | 0.95 | HTR6 (0.69) | ESR1CYP19A1ESRRGESR2LMNA | |
| SCHEMBL906307 | 0.95 | HTR6 (0.69) | ESR1CYP19A1ESRRGESR2LMNA | |
| SCHEMBL5725379 | 0.95 | HTR6 (0.69) | ESR1CYP19A1ESRRGESR2LMNA | |
| SCHEMBL9097768 | 0.91 | ESR1 (0.63) | ESR1CYP19A1ESRRGESR2LMNA | |
| SCHEMBL9097781 | 0.91 | ESR1 (0.63) | ESR1CYP19A1ESRRGESR2LMNA | |
| SCHEMBL9097774 | 0.91 | ESR1 (0.63) | ESR1CYP19A1ESRRGESR2LMNA | |
| SCHEMBL23183595 | 0.89 | ESR1 (0.82) | ESR1CYP19A1ESRRGESR2CYP1A2 | |
| Endoxifen SCHEMBL14391818 | 0.86 | ESR1 (1.00) | ESR1CYP19A1ESRRGESR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186185-A1 | Using toremifene and/or analog or metabolite; reducing incidence of premalignant lesions | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2004-09-23 | — | — | US | claimed |
| US-20040092602-A1 | Administering toremifene | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2004-05-13 | — | — | US | claimed |
| US-6413535-B1 | ADMINISTERING CHLORINATED PHENYL COMPOUND | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION | 2002-07-02 | — | — | US | claimed |
| US-5491173-A | ESTROGENIC, ANTIESTROGENIC AGENTS, ANTITUMOR AGENTS | ORION-YHTYMA OY (FI) | 1996-02-13 | — | — | US | claimed |
| EP-2277514-A1 | A method for chemoprevention of prostate cancer | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2011-01-26 | — | — | EP | disclosed |
| US-7378445-B2 | Treatment of prostate cancer | PEPLIN RESEARCH PTY. LTD. (AU) | 2008-05-27 | — | — | US | disclosed |
| US-20060287400-A1 | benign prostatic hyperplasia, prostate intraepithelial neoplasia (PIN), or an abnormally high level of circulating prostate specific antibody (PSA), | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2006-12-21 | — | — | US | disclosed |
| US-20060105994-A1 | Treatment of prostate cancer | PEPLIN RESEARCH PTY LTD. (AU) | 2006-05-18 | — | — | US | disclosed |
| EP-1003496-B1 | MEDICAMENT FOR TREATING PROSTATE INTRAEPITHELIAL NEOPLASIA | UNIV TENNESSEE RES CORP (US) | 2004-11-24 | — | — | EP | disclosed |
| EP-1475087-A2 | A method for chemoprevention of prostate cancer | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2004-11-10 | — | — | EP | disclosed |
| US-20040186185-A1 | Using toremifene and/or analog or metabolite; reducing incidence of premalignant lesions | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2004-09-23 | — | — | US | disclosed |
| US-20040176470-A1 | suppressing, inhibiting, or reducing the incidence of pre-malignant lesions of prostate cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2004-09-09 | — | — | US | disclosed |
| US-6413533-B1 | ADMINISTERING ANTIESTROGEN | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION | 2002-07-02 | — | — | US | disclosed |
| US-6410043-B1 | Method for chemoprevention of prostate cancer | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION | 2002-06-25 | — | — | US | disclosed |
| US-6204295-B1 | Antioxidant compounds | ORION CORPORATION (FI) | 2001-03-20 | — | — | US | disclosed |
| EP-1003496-A1 | METHOD FOR CHEMOPREVENTION OF PROSTATE CANCER | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999056739-A1 | A METHOD FOR CHEMOPREVENTION OF PROSTATE CANCER | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 1999-11-11 | — | — | WO | disclosed |
| EP-0910354-A1 | ANTIOXIDANT COMPOUNDS | ORION-YHTYMA OY (FI) | 1999-04-28 | — | — | EP | disclosed |
| WO-1997041847-A1 | ANTIOXIDANT COMPOUNDS | Orion-Yhtymä Oy (FI) | 1997-11-13 | — | — | WO | disclosed |
| US-5491173-A | ESTROGENIC, ANTIESTROGENIC AGENTS, ANTITUMOR AGENTS | ORION-YHTYMA OY (FI) | 1996-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176470-A1 | suppressing, inhibiting, or reducing the incidence of pre-malignant lesions of prostate cancer | ACP3, KLK3, MKI67 | ESR1 253/4885CYP19A1 115/4885ESRRG 431/4885 |
| US-20040186185-A1 | Using toremifene and/or analog or metabolite; reducing incidence of premalignant lesions | AR, OPRL1, NR5A1 | ESR1 19/4885CYP19A1 15/4885ESRRG 181/4885 |
| US-20060105994-A1 | Treatment of prostate cancer | ACP3, KLK3, BPHL | ESR1 209/4885CYP19A1 110/4885ESRRG 165/4885 |
| US-20060287400-A1 | benign prostatic hyperplasia, prostate intraepithelial neoplasia (PIN), or an abnormally high level of circulating prostate specific antibody (PSA), | KLK3, ACP3, BPHL | ESR1 767/4885CYP19A1 86/4885ESRRG 3107/4885 |
| US-20040092602-A1 | Administering toremifene | OPRL1, OPRK1, NR5A1 | ESR1 26/4885CYP19A1 28/4885ESRRG 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.